CorMedix (CRMD) Revenue & Revenue Breakdown
CorMedix Revenue Highlights
Latest Revenue (Y)
$43.47B
Latest Revenue (Q)
$39.08M
Main Geography (Y)
Europe
CorMedix Revenue by Period
CorMedix Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $43.47B | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $65.41K | -65.74% |
| 2021-12-31 | $190.94K | -20.19% |
| 2020-12-31 | $239.23K | -15.55% |
| 2019-12-31 | $283.27K | -34.09% |
| 2018-12-31 | $429.80K | 30.51% |
| 2017-12-31 | $329.33K | 46.95% |
| 2016-12-31 | $224.10K | 6.65% |
| 2015-12-31 | $210.13K | 11.02% |
| 2014-12-31 | $189.27K | 9358.97% |
| 2013-12-31 | $2.00K | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | - |
CorMedix generated $43.47B in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 15346765.94% compared to the same period a year ago.
CorMedix Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $39.08M | 25.22% |
| 2024-12-31 | $31.21M | 172.43% |
| 2024-09-30 | $11.46M | 1321.14% |
| 2024-06-30 | $806.12K | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $304.11K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $29.70K | 335.70% |
| 2022-09-30 | $6.82K | -67.92% |
| 2022-06-30 | $21.25K | 178.33% |
| 2022-03-31 | $7.64K | -86.46% |
| 2021-12-31 | $56.40K | 48.07% |
| 2021-09-30 | $38.09K | 365.00% |
| 2021-06-30 | $8.19K | -90.72% |
| 2021-03-31 | $88.26K | 58.42% |
| 2020-12-31 | $55.71K | -40.11% |
| 2020-09-30 | $93.02K | 465.71% |
| 2020-06-30 | $16.44K | -77.80% |
| 2020-03-31 | $74.05K | 198.86% |
| 2019-12-31 | $24.78K | -58.38% |
| 2019-09-30 | $59.53K | 68.80% |
| 2019-06-30 | $35.27K | -78.46% |
| 2019-03-31 | $163.69K | 517.17% |
| 2018-12-31 | $26.52K | -92.88% |
| 2018-09-30 | $372.51K | 4833.31% |
| 2018-06-30 | $7.55K | -67.47% |
| 2018-03-31 | $23.21K | -74.92% |
| 2017-12-31 | $92.53K | 51.50% |
| 2017-09-30 | $61.08K | -55.15% |
| 2017-06-30 | $136.17K | 244.21% |
| 2017-03-31 | $39.56K | -67.50% |
| 2016-12-31 | $121.72K | 173.82% |
| 2016-09-30 | $44.45K | 169.22% |
| 2016-06-30 | $16.51K | -60.14% |
| 2016-03-31 | $41.43K | 80.54% |
| 2015-12-31 | $22.95K | -36.17% |
| 2015-09-30 | $35.95K | -70.04% |
| 2015-06-30 | $119.97K | 283.74% |
| 2015-03-31 | $31.26K | -63.18% |
| 2014-12-31 | $84.90K | 61.90% |
| 2014-09-30 | $52.44K | 32.00% |
| 2014-06-30 | $39.73K | 225.57% |
| 2014-03-31 | $12.20K | 509.85% |
| 2013-12-31 | $2.00K | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | - |
CorMedix generated $39.08M in revenue during Q1 2025, up 25.22% compared to the previous quarter, and up 12851.16% compared to the same period a year ago.
CorMedix Revenue Breakdown
CorMedix Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 |
|---|---|---|
| Europe | $190.94K | $237.03K |
Latest
CorMedix's latest annual revenue breakdown by geography, as of Dec 21: Europe (100.00%).
CorMedix Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CRMD | CorMedix | $43.47B | $39.08M |
| DNA | Ginkgo Bioworks | $227.04M | $48.32M |
| IOVA | Iovance Biotherapeutics | $164.07M | $49.32M |
| VALN | Valneva SE | $153.70M | $32.75M |
| URGN | UroGen Pharma | $90.40M | $20.25M |
| GERN | Geron | $76.50M | $49.04M |
| VIR | Vir Bio | $74.20M | $1.21M |
| ABUS | Arbutus Biopharma | $6.17M | $10.74M |
| RZLT | Rezolute | - | - |
| AVBP | ArriVent BioPharma | - | - |